entertainment -WSS

entertainment

author：focus 2025-09-04 05:34:37 - browse：79

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

hotspot

WSS

UnitedHealth’s board chair also owns a personal investment firm

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Headspace, Meta partner to launch VR meditation app for Quest

Sen. Paul opposes bill to ban Chinese biotechs

Change Healthcare cyberattack prompts Medicare loan program

Air quality improving but still lags in Black, Hispanic communities

entertainment

entertainment

focus

23andMe had bad news about my health. I wish a person had delivered it

NEJM study link tiny plastics in blood vessels to heart problems

In age of alternative facts, a scholarly course on calling out crap

Eli Lilly expects to double planned employment in Boston center

Moonlake's readout produced a cash windfall. Risks remain

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senate committee scrutinizes Medicare Advantage brokers

Cancer drug shortages should be causing more outrage

RSV shot was 90% effective at preventing hospitalizations in kids

knowledge

Amylyx ALS drug fails large clinical trial

Researchers explore possible ties between long Covid, menopause

Lawmakers consider Medicare pay reforms for doctors

FDA struggles to regulate food additives, sometimes for decades

STAT Readout Newsletter: Today's biggest biotech updates

STAT Summit: GSK CEO on pharma giant's new direction

entertainment

hotspot

hotspot

knowledge